Cathie Wood’s ARK shifts focus, buys AMD stock and trims CRISPR

Cathie Wood’s ARK ETFs have made significant adjustments to their portfolios, as seen in the daily trade report for Tuesday, 29 April 2025. The largest transaction of the day involved the sale of CRISPR Therapeutics AG (NASDAQ:CRSP), with ARK’s flagship ARKK ETF offloading 92,782 shares, resulting in a total dollar value of $3,514,582. This move comes after a similar sale on the previous day, suggesting a strategic reduction in ARK’s position in the gene-editing company.

In contrast, ARK has increased its stake in Advanced Micro Devices Inc (NASDAQ:AMD), purchasing 7,786 shares through its ARKW ETF, amounting to $750,492. This buy adds to the previous acquisitions of AMD stock last week, indicating a growing confidence in the semiconductor manufacturer.

Another notable trade was the sale of 67,053 shares of Schrödinger Inc (NASDAQ:SDGR) by the ARKG ETF, valued at $1,726,614. This follows a pattern of selling the computational drug discovery company’s shares, as ARK also reduced its holdings in SDGR the day before.

The ARKK ETF also parted with 2,865 shares of Meta Platforms Inc (NASDAQ:META), totaling $1,575,005. This sale aligns with a trend of ARK reducing its exposure to the social media giant, as evidenced by the previous week’s trades.

On the buying side, ARK’s ARKK ETF invested in several biotech firms, including a $525,005 purchase of 61,911 shares of Intellia Therapeutics Inc (NASDAQ:NTLA), a $764,950 acquisition of 5,000 shares of Natera Inc (NASDAQ:NTRA), and a modest $3,841 for 3,400 shares of Pacific Biosciences of California Inc (NASDAQ:PACB). These trades suggest a continued interest in the genomic sector.

Additionally, ARK’s ARKW ETF bought 12,182 shares of Shopify Inc (NYSE:NASDAQ:SHOP) for $1,200,779, and the ARKG ETF added 60,264 shares of Personalis Inc (NASDAQ:PSNL) at a value of $225,990. ARK’s ARKQ ETF made a minor purchase of 100 shares of Symbotic Inc (NASDAQ:SYM) for $2,200, while the ARKK ETF bought 7,044 shares of 10X Genomics Inc (NASDAQ:TXG) for $59,733.

These trades reflect ARK’s ongoing strategy of investing in innovative companies with disruptive potential while adjusting its holdings in response to market dynamics and company performance. Investors will be watching closely to see how these moves play out in the evolving landscape of technology and biotechnology sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.